Semaglutide vs Retatrutide
One receptor vs three. The metabolic peptide landscape has shifted, here is the research comparison.
What is the difference
Semaglutide (GLP-1 single agonist) has a decade of published data. Retatrutide (GLP-1 + GIP + glucagon triple agonist) is the newest investigational peptide from Eli Lilly. This page compares their mechanisms, formats, and research profiles.
| Property | Semaglutide | Retatrutide |
|---|---|---|
| Mechanism | GLP-1 receptor agonist (single) | Triple agonist: GLP-1 + GIP + glucagon |
| Developer | Novo Nordisk | Eli Lilly (Phase 2/3) |
| Receptors activated | 1 (GLP-1) | 3 (GLP-1 + GIP + glucagon) |
| Common formats | 5 mg lyophilized powder | 10 mg / 20 mg lyophilized powder |
| Published data | Extensive. Years of trials | Growing. Phase 2 complete |
| VND price | 1,100,000 VND | from 1,700,000 VND |
Bottom line
Triple-agonist research vs established single-receptor data. Two different tools for different research questions, both listed.
Ask about Semaglutide or Retatrutide
Format, price and timing confirmed before payment. Free swabs + syringe with every order.
Common questions
Which of these peptides is better for research?
Neither is "better": Semaglutide and Retatrutide address different research questions through different mechanisms. The choice depends on the research protocol.
Can I order both peptides from this catalog?
Yes. Semaglutide and Retatrutide are listed as separate items. 2+ peptides = free bacteriostatic water 3 ml. Price and availability confirmed before payment.
Do I need a separate inquiry for each peptide?
No. You can ask about both in one Telegram message. Mention the names and formats and the manager will confirm availability, total and timing.